USPH Q4 2025 earnings call highlights: record visits, EBITDA growth, 2026 guidance ($102–$106M) and hospital partnerships.
Higher average selling prices, and a 100% attach rate for AI cloud software highlight Nebius' sticky business model. Find out ...
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for olezarsen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results